| ID Source | ID |
|---|---|
| PubMed CID | 4368 |
| CHEMBL ID | 70176 |
| SCHEMBL ID | 6129930 |
| MeSH ID | M0371199 |
| Synonym |
|---|
| n-hydroxy-2-[(4-methoxy-benzenesulfonyl)-pyridin-3-ylmethyl-amino]-3-methyl-benzamide |
| WAY , |
| way-151693 |
| DB02071 |
| n-hydroxy-2-{[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino}-3-methylbenzamide |
| 1FLS , |
| bdbm50096463 |
| n-hydroxy-2-(4-methoxy-n-(pyridin-3-ylmethyl)phenylsulfonamido)-3-methylbenzamide |
| CHEMBL70176 , |
| n-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbenzamide |
| SCHEMBL6129930 |
| n-hydroxy-2-{[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino}-3-methylbenzamide |
| Q27093149 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, COLLAGENASE-3 | Homo sapiens (human) | IC50 (µMol) | 0.0330 | 0.0330 | 0.0330 | 0.0330 | AID977608 |
| Tumor necrosis factor | Homo sapiens (human) | IC50 (µMol) | 0.4107 | 0.2000 | 0.6791 | 1.3000 | AID215421 |
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 0.2153 | 0.0002 | 0.8502 | 10.0000 | AID108729; AID109062; AID109089; AID109091 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 0.0057 | 0.0000 | 0.7053 | 10.0000 | AID108004; AID108286; AID108311; AID108313; AID310906 |
| Collagenase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0097 | 0.0000 | 0.7675 | 10.0000 | AID109248; AID109399; AID109414; AID109539; AID310907 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | IC50 (µMol) | 0.3657 | 0.0002 | 1.0140 | 10.0000 | AID210021; AID215421 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID108311 | In vitro inhibition of Matrix metalloprotease-9. | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines. |
| AID108286 | Inhibition of Matrix metalloprotease-9 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. |
| AID109089 | In vitro inhibition of Matrix metalloprotease-1. | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines. |
| AID215421 | In vitro inhibition of TNF-alpha converting enzyme. | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines. |
| AID109091 | In vitro inhibition of Matrix metalloprotease-1 | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. |
| AID109539 | In vitro inhibition of Matrix metalloprotease-13. | 2001 | Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22 | The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines. |
| AID108313 | In vitro ability to inhibit matrix metalloprotease-9. | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. |
| AID108438 | Dose at which the compound was equipotent with CGS-27023 against matrix metalloprotease-9 in the dialysis tubing implant assay | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID108729 | Inhibitory activity against Matrix metalloprotease-1 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID108439 | Tested the po dose effective against Matrix metalloprotease-9 in the dialysis tubing implant assay | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID108004 | Inhibitory activity against Matrix metalloprotease-9 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID310907 | Inhibition of MMP13 | 2007 | Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6 | Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. |
| AID109062 | Inhibition of Matrix metalloprotease-1 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. |
| AID310906 | Inhibition of MMP9 | 2007 | Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6 | Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. |
| AID109248 | Inhibitory activity against Matrix metalloprotease-13 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID182046 | In vivo inhibition of collagen degradation in a rat sponge wrapped cartilage model at a dose of 50 mg/kg ip | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID109399 | Inhibition of Matrix metalloprotease-13 | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. |
| AID210021 | In vitro inhibition of TNF-alpha converting enzyme (TACE) | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. |
| AID54303 | Inhibition of collagen degradation in a bovine articular cartilage assay | 2001 | Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2 | The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. |
| AID109414 | Inhibition of matrix metalloprotease-13 | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2000 | Journal of molecular biology, Sep-22, Volume: 302, Issue:3 | High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2000 | Journal of molecular biology, Sep-22, Volume: 302, Issue:3 | High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||